### Protocol

**Placental and Umbilical Cord Blood as a Source of Stem Cells**

(70150)

<table>
<thead>
<tr>
<th>Medical Benefit</th>
<th>Effective Date: 04/01/13</th>
<th>Next Review Date: 03/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preauthorization</td>
<td>Yes</td>
<td>Review Dates: 04/07, 05/08, 07/11, 07/12, 07/13, 07/14, 07/15, 11/15, 11/16, 03/17</td>
</tr>
</tbody>
</table>

**Preauthorization is required and must be obtained through Case Management.**

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: • With an appropriate indication for allogeneic stem cell transplant</td>
<td>Interventions of interest are: • Cord blood as a source of stem cells</td>
<td>Comparators of interest are: • Stem cells from a source other than cord blood</td>
<td>Relevant outcomes include: • Overall survival • Disease-specific survival • Resource utilization • Treatment-related mortality</td>
</tr>
<tr>
<td>Individuals: • With an unspecified potential future need for stem cell transplant</td>
<td>Interventions of interest are: • Prophylactic collection and storage of cord blood</td>
<td>Comparators of interest are: • Usual care without prophylactic storage of cord blood</td>
<td>Relevant outcomes include: • Overall survival • Disease-specific survival • Resource utilization • Treatment-related mortality</td>
</tr>
</tbody>
</table>

**Description**

This protocol addresses the collection, storage, and transplantation of placental and umbilical cord blood (“cord blood”) as a source of stem cells for allogeneic and autologous stem cell transplantation. Potential indications for the use of cord blood are not addressed herein; they are discussed in the disease-specific protocols.

**Summary of Evidence**

For individuals who have an appropriate indication for allogeneic stem cell transplant who receive cord blood as a source of stem cells, the evidence includes a number of observational studies, a meta-analysis of observational studies, and a randomized controlled trial (RCT) comparing outcomes after single- or double-cord blood units. Relevant outcomes are overall survival, disease-specific survival, resource utilization, and treatment-related mortality. The meta-analysis of observational studies found similar survival outcomes and lower graft-versus-host disease after cord blood transplantation than bone marrow transplantation. In the RCT, survival rates were similar after single- and double-unit cord blood transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have an unspecified potential future need for stem cell transplant who receive prophylactic collection and storage of cord blood, the evidence includes no published studies. Relevant outcomes are overall survival, disease-specific survival, resource utilization, and treatment-related mortality. No evidence was
identified on the safety or effectiveness of autologous cord blood transplantation from prophylactically stored cord blood for the treatment of malignant neoplasms. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy

Transplantation of cord blood stem cells from related or unrelated donors may be considered medically necessary in patients with an appropriate indication for allogeneic stem-cell transplant.

Transplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations.

Collection and storage of cord blood from a neonate may be considered medically necessary when an allogeneic transplant is imminent in an identified recipient with a diagnosis that is consistent with the possible need for allogeneic transplant.

Prophylactic collection and storage of cord blood from a neonate may be considered not medically necessary when proposed for some unspecified future use as an autologous stem-cell transplant in the original donor, or for some unspecified future use as an allogeneic stem-cell transplant in a related or unrelated donor.

Policy Guidelines

Please refer to the separate protocols for specific conditions/diseases that have patient selection criteria regarding situations for which allogeneic stem-cell transplantation may be considered medically necessary.

Individual transplant facilities may have their own additional requirements or protocols that must be met in order for the patient to be eligible for a transplant at their facility.

Medicare Advantage

If a transplant is needed, we arrange to have the transplant center review and decide whether the patient is an appropriate candidate for the transplant.

Background

A variety of malignant diseases and nonmalignant bone marrow disorders are treated with myeloablative therapy followed by infusion of allogeneic stem and progenitor cells collected from immunologically compatible donors, either family members or an unrelated donor identified through a bone marrow donor bank. In some cases, a suitable donor is not found.

Blood harvested from the umbilical cord and placenta shortly after delivery of neonates contains stem and progenitor cells capable of restoring hematopoietic function after myeloblation. This cord blood has been used as an alternative source of allogeneic stem cells. Cord blood is readily available and is thought to be antigenically “naive,” thus potentially minimizing the incidence of graft-versus-host disease and permitting the broader use of unrelated cord blood transplants. Unrelated donors are typically typed at low resolution for human leukocyte antigen (HLA)-A and -B and at high resolution only for HLA-DR; HLA matching at four of six loci is considered acceptable. Under this matching protocol, an acceptable donor can be identified for almost any patient.

Several cord blood banks have been created in the United States and Europe. In addition to obtaining cord blood for specific related or unrelated patients, some cord blood banks collect and store neonate cord blood for some unspecified future use in the unlikely event that the child develops a condition that would require autologous
transplantation. In addition, some neonate cord blood is collected and stored for use by a sibling in whom an allogeneic transplant is anticipated due to a history of leukemia or other condition requiring allogeneic transplant.

Standards and accreditation for cord blood banks are important for assisting transplant programs in knowing whether individual banks have quality control measures in place to address issues such as monitoring cell loss, change in potency, and prevention of product mix-up.\(^1\) Two major organizations are working toward these accreditation standards: the International NetCord Foundation (NetCord)/Foundation for the Accreditation of Cellular Therapy (FACT) and the American Association of Blood Banks. NetCord and FACT developed and implemented a program of voluntary inspection and accreditation for cord blood banking. NetCord and FACT publish international standards for cord blood banks that include voluntary standards for collection, testing, processing, storage, and release of cord blood products.\(^2\)

**Regulatory Status**

According to the U.S. Food and Drug Administration (FDA), cord blood stored for potential use by a patient unrelated to the donor meets the definitions of “drug” and “biological products.” As such, products must be licensed under a biologics license application or an investigational new drug application before use. Facilities that prepare cord blood units only for autologous and/or first- or second-degree relatives are required to register and list their products, adhere to Good Tissue Practices issued by FDA, and use applicable processes for donor suitability determination.\(^3\)

**Related Protocols**

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Allogeneic Hematopoietic Stem Cell Transplantation for Genetic Diseases and Acquired Anemias

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Hematopoietic Cell Transplantation for Waldenström Macroglobulinemia

Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Hematopoietic Stem Cell Transplantation for Autoimmune Diseases

Hematopoietic Stem Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia

Hematopoietic Stem Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Stem Cell Transplantation for Miscellaneous Solid Tumors in Adults

Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell Tumors
Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.


